CS
CSTL
CASTLE BIOSCIENCES INC
$20.53
+2.52%
$607.5M
No data for this timeframe.
Vol
Market Cap$607.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$138.6M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 16S
Insider Net $-$3.8M
SEC Reports7
Press Releases2
Recent Activity
May 7, 2026
SEC
CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10b5-1 trading plan ad
144 — Impact 3/10
May 7, 2026
Insider
MAETZOLD DEREK J sold 6,214 shares
Pres. & Chief Exec. Officer @ $2.39 ($14.9K)
May 7, 2026
Insider
MAETZOLD DEREK J sold 5,308 shares
Pres. & Chief Exec. Officer @ $22.08 ($117.2K)
May 7, 2026
Insider
MAETZOLD DEREK J sold 6,214 shares
Pres. & Chief Exec. Officer @ $0.00 ($0.00)
May 6, 2026
earnings_calendar
CSTL Q1 2026 Earnings Scheduled — 2026-05-06
Apr 8, 2026
SEC
Castle Biosciences Inc. (CSTL) has filed a definitive proxy statement for its upcoming annual shareholder meeting. The f
DEFA14A — Impact 3/10
Mar 19, 2026
SEC
Castle Biosciences CEO Derek Maetzold sold 49,953 shares in the past week through open-market transactions, totaling app
CLUSTER — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
84,066 shares ($3.3M)
Price Targets
$45.88
+123.4% upside
Strong Buy
Current $20.54
Low $40.00
Median $46.00
High $52.00
8 analysts
$40.00
$52.00
Analyst Ratings
7Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | BTIG | MAINTAIN | Buy → Buy |
| May 7, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Feb 27, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| Jan 26, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 ▼ -29.4% | $-0.53 — $-0.30 | -364% YoY | 8 |
| Next Q | $-0.28 ▼ -46.4% | $-0.41 — $-0.14 | -1300% YoY | 8 |
| Current FY | $-1.36 ▼ -15.6% | $-1.74 — $-0.84 | -64% YoY | 8 |
| Next FY | $-0.90 ▼ -65.7% | $-1.67 — $-0.37 | 34% YoY | 8 |
Latest Reports
NEUTRAL
144
3/10
CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10b5-1 trading plan ad
May 7, 2026
NEUTRAL
DEFA14A
3/10
Castle Biosciences Inc. (CSTL) has filed a definitive proxy statement for its upcoming annual shareholder meeting. The f
Apr 8, 2026
BULLISH
Press
7/10
Castle Biosciences announced publication of data from a large prospective study showing its DecisionDx-Melanoma i31-SLNB
Mar 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $85.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $19.2M | ADD |
| BANK OF AMERICA CORP | $10.2M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $9.4M | NEW |
| MORGAN STANLEY | $7.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 7, 2026 | MAETZOLD DEREK | M | $14.9K |
| May 7, 2026 | MAETZOLD DEREK | SELL | $117.2K |
| May 7, 2026 | MAETZOLD DEREK | M | $0.00 |
| Apr 21, 2026 | MAETZOLD DEREK | SELL | $13.8K |
| Apr 21, 2026 | MAETZOLD DEREK | M | $1.3K |
8 institutional holders with $138.6M total value (3,562,624 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,199,829 | $85.6M | 61.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 493,100 | $19.2M | 13.8% | ADD +39.9% |
| 3 | BANK OF AMERICA CORP /DE/ | 263,019 | $10.2M | 7.4% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 242,535 | $9.4M | 6.8% | NEW |
| 5 | MORGAN STANLEY | 203,577 | $7.9M | 5.7% | ADD +60.9% |
| 6 | TWO SIGMA INVESTMENTS, LP | 84,066 | $3.3M | 2.4% | DOUBLED +227.1% |
| 7 | FMR LLC | 42,286 | $1.6M | 1.2% | ADD +48.2% |
| 8 | WELLS FARGO & COMPANY/MN | 34,212 | $1.3M | 1.0% | ADD +42.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 25,700 | 84,066 | +227.1% | $3.3M | 2025-Q4 |
| FMR LLC | ADD | 28,542 | 42,286 | +48.2% | $1.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 23,979 | 34,212 | +42.7% | $1.3M | 2025-Q4 |
| MORGAN STANLEY | ADD | 167,588 | 269,631 | +60.9% | $6.1M | 2025-Q3 |
| UBS Group AG | DOUBLED | 48,759 | 363,848 | +646.2% | $7.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 139,785 | 28,241 | -79.8% | $576.7K | 2025-Q2 |
| FMR LLC | DOUBLED | 1,156 | 24,000 | +1976.1% | $490.1K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 884,012 | 272,882 | -69.1% | $5.5M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 306,677 | 211,793 | -30.9% | $4.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 139,785 | — | $2.8M | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 839,000 | 48,759 | -94.2% | $976.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 694,916 | 884,012 | +27.2% | $23.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 80,534 | 839,000 | +941.8% | $22.4M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 489,562 | 685,000 | +39.9% | $18.3M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 11,915 | 15,375 | +29.0% | $409.7K | 2024-Q4 |
| MORGAN STANLEY | ADD | 249,380 | 396,919 | +59.2% | $11.3M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 274,761 | — | $7.8M | 2024-Q3 |
6 unique insiders with 16 transactions. Net insider value: -$3.8M ($0.00 bought, $3.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 7, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 6,214 | $2.39 | $14.9K |
| May 7, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 5,308 | $22.08 | $117.2K |
| May 7, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 6,214 | $0.00 | $0.00 |
| Apr 21, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 550 | $25.10 | $13.8K |
| Apr 21, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 550 | $2.39 | $1.3K |
| Apr 21, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 550 | $0.00 | $0.00 |
| Apr 6, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 6,214 | $0.00 | $0.00 |
| Apr 6, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 6,214 | $25.03 | $155.5K |
| Apr 6, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 6,214 | $2.39 | $14.9K |
| Mar 26, 2026 | Cotton Rodney | Director | M | 5,329 | $0.00 | $0.00 |
| Mar 26, 2026 | Cotton Rodney | Director | M | 5,329 | $0.00 | $0.00 |
| Mar 26, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 550 | $2.39 | $1.3K |
| Mar 26, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 550 | $25.55 | $14.1K |
| Mar 26, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 550 | $0.00 | $0.00 |
| Mar 18, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 650 | $25.39 | $16.5K |
| Mar 17, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 18,650 | $25.93 | $483.6K |
| Mar 16, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 17,449 | $25.96 | $453.0K |
| Mar 13, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 13,204 | $25.45 | $336.0K |
| Mar 12, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 23,179 | $25.28 | $585.9K |
| Mar 12, 2026 | Juvenal Tobin W | Chief Commercial Officer | SELL | 20,863 | $25.24 | $526.6K |
| Mar 11, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 6,226 | $0.00 | $0.00 |
| Mar 11, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 6,226 | $2.39 | $14.9K |
| Mar 11, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 17,310 | $26.11 | $451.9K |
| Mar 5, 2026 | Cole G Bradley | Director | M | 4,748 | $0.00 | $0.00 |
| Mar 5, 2026 | Cole G Bradley | Director | M | 4,748 | $3.38 | $16.0K |
| Mar 5, 2026 | Cole G Bradley | Director | SELL | 4,748 | $28.44 | $135.0K |
| Mar 5, 2026 | Stokes Frank | Chief Financial Officer | SELL | 6,001 | $27.98 | $167.9K |
| Mar 4, 2026 | Oelschlager Kristen M | Chief Operating Officer | M | 25,771 | $0.00 | $0.00 |
| Mar 4, 2026 | Oelschlager Kristen M | Chief Operating Officer | M | 13,811 | $0.00 | $0.00 |
| Mar 4, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 59,097 | $0.00 | $0.00 |
| Mar 4, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | M | 31,110 | $0.00 | $0.00 |
| Mar 4, 2026 | Stokes Frank | Chief Financial Officer | M | 12,186 | $0.00 | $0.00 |
| Mar 4, 2026 | Stokes Frank | Chief Financial Officer | M | 3,800 | $0.00 | $0.00 |
| Mar 4, 2026 | Juvenal Tobin W | Chief Commercial Officer | M | 25,771 | $0.00 | $0.00 |
| Mar 4, 2026 | Juvenal Tobin W | Chief Commercial Officer | M | 13,811 | $0.00 | $0.00 |
| Mar 4, 2026 | Stokes Frank | Chief Financial Officer | M | 24,146 | $0.00 | $0.00 |
| Mar 3, 2026 | Oelschlager Kristen M | Chief Operating Officer | F | 2,427 | $27.57 | $66.9K |
| Mar 3, 2026 | Oelschlager Kristen M | Chief Operating Officer | A | 48,367 | $0.00 | $0.00 |
| Mar 3, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | A | 102,597 | $0.00 | $0.00 |
| Mar 3, 2026 | Stokes Frank | Chief Financial Officer | A | 48,367 | $0.00 | $0.00 |
| Mar 3, 2026 | Juvenal Tobin W | Chief Commercial Officer | F | 3,716 | $27.57 | $102.5K |
| Mar 3, 2026 | Juvenal Tobin W | Chief Commercial Officer | A | 48,367 | $0.00 | $0.00 |
| Mar 3, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | F | 19,043 | $27.57 | $525.0K |
| Mar 3, 2026 | Stokes Frank | Chief Financial Officer | SELL | 5,300 | $27.32 | $144.8K |
| Feb 4, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 646 | $37.82 | $24.4K |
| Feb 3, 2026 | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | SELL | 3,200 | $39.91 | $127.7K |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 3 neutral. Avg impact: 4.9/10.
NEUTRAL
144
3/10
CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10
May 7, 2026
NEUTRAL
DEFA14A
3/10
Castle Biosciences Inc. (CSTL) has filed a definitive proxy statement for its upcoming annual shareh
Apr 8, 2026
BEARISH
CLUSTER
6/10
Castle Biosciences CEO Derek Maetzold sold 49,953 shares in the past week through open-market transa
Mar 19, 2026
BEARISH
CLUSTER
7/10
CEO Derek Maetzold and Chief Commercial Officer Juvenal Tobin sold a combined $2.4M in open-market t
Mar 17, 2026
BEARISH
CLUSTER
7/10
Multiple C-suite executives at Castle Biosciences sold shares in a concentrated 7-day window, includ
Mar 16, 2026
BEARISH
CLUSTER
5/10
Castle Biosciences CEO Derek Maetzold sold a total of 40,489 shares in the past week, generating app
Mar 13, 2026
NEUTRAL
CLUSTER
3/10
Castle Biosciences insiders executed a cluster of transactions over the past week, primarily involvi
Mar 9, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 7 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$45.88 mean target
+123.4% upside
Strong Buy (1.00)
$40.00 Low
$52.00 High
| Metric | Value |
|---|---|
| Current Price | $20.54 |
| Target Low | $40.00 |
| Target Mean | $45.88 |
| Target Median | $46.00 |
| Target High | $52.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.53 | $-0.30 | -364.2% | -29.4% | 2↑ 6↓ | $0.1B | 0.1% | 8 |
| Next Q 2026-09-30 |
$-0.28 | $-0.41 | $-0.14 | -1300.0% | -46.4% | 2↑ 6↓ | $0.1B | 8.8% | 8 |
| Current FY 2026-12-31 |
$-1.36 | $-1.74 | $-0.84 | -63.7% | -15.6% | 3↑ 5↓ | $0.3B | 1.3% | 8 |
| Next FY 2027-12-31 |
$-0.90 | $-1.67 | $-0.37 | 33.7% | -65.7% | 2↑ 6↓ | $0.4B | 12.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.396 | |
| 7d ago | $-0.306 | -0.090 |
| 30d ago | $-0.306 | -0.090 |
| 60d ago | $-0.306 | -0.090 |
| 90d ago | $-0.362 | -0.034 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 7, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Jan 26, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings_calendar
CSTL Q1 2026 Earnings Scheduled — 2026-05-06
Mar 13, 2026
fda
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma’s integrated SLNB test result.
Mar 9, 2026
fda
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB
Mar 4, 2026
other
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
Mar 3, 2026
other
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time.
Feb 26, 2026
earnings_calendar
CSTL Q4 2025 Earnings After Market Close — 2026-02-26
Feb 2, 2026
short_interest
FTD: CSTL — 19,689 shares ($0.8M) failed to deliver
Settlement: 20260202, Price: $39.39, FTD Value: $775,549.71, CASTLE BIOSCIENCES INC COM